SRF617

American Association for Cancer Research Annual Meeting, June 2020

 

Poster: The fully human antibody SRF617 is a potent enzymatic inhibitor of CD39 with strong immunomodulatory activity

Society for Immunotherapy of Cancer Annual Meeting, November 2019

Presentation: Targeting the Adenosine Axis to Treat Cancer

Brisbane Immunotherapy Conference, May 2019